Paddington Testing Company Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$162,966	10
2024	Research	$272,511	21
2023	Research	$104,392	7
2022	Research	$28,222	6
2021	Research	$306,256	7
2020	Research	$469,957	14
2019	Research	$27,018	4

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $789,459 25 payments
Eli Lilly and Company $457,105 18 payments
Janssen Research & Development, LLC $83,080 16 payments
Galderma Laboratories, L.P. $22,190 4 payments
Horizon Therapeutics plc $17,251 2 payments
AbbVie, Inc. $1,952 3 payments
Ucb SA $284 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Atopic Dermatitis $189,510 5 payments
Psor-025/20200063 (Discreet) $174,358 2 payments
ASCEND P3 AD Extension $154,944 2 payments
Efficacy Safety Study of Apremilast in Subjects With Moderate to Severe Genital Psoriasis (PSOR-025) $135,217 2 payments
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) $135,132 1 payment
Efficacy Safety Study of Apremilast in Subjects With Moderate to Severe Genital Psoriasis(PSOR-025) $123,904 8 payments
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis $99,553 2 payments
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Psoriasis $77,031 5 payments
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $71,731 14 payments
A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis $27,837 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.